Wall Street analysts predict that Cellectis S.A. (NASDAQ:CLLS – Get Rating) will report $30.00 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Cellectis’ earnings, with the highest sales estimate coming in at $43.50 million and the lowest estimate coming in at $16.50 million. Cellectis posted sales of $14.62 million during the same quarter last year, which suggests a positive year over year growth rate of 105.2%. The firm is scheduled to announce its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Cellectis will report full year sales of $103.35 million for the current financial year, with estimates ranging from $62.00 million to $144.70 million. For the next year, analysts expect that the company will post sales of $120.60 million, with estimates ranging from $89.00 million to $152.20 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Cellectis.
Cellectis (NASDAQ:CLLS – Get Rating) last announced its earnings results on Thursday, March 3rd. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.50. The business had revenue of $13.66 million during the quarter, compared to analyst estimates of $12.30 million. Cellectis had a negative net margin of 312.64% and a negative return on equity of 53.48%. During the same period in the previous year, the business posted ($0.95) earnings per share.
A number of institutional investors and hedge funds have recently made changes to their positions in CLLS. Long Focus Capital Management LLC purchased a new position in shares of Cellectis in the fourth quarter worth $9,390,000. Jane Street Group LLC increased its position in Cellectis by 166.5% during the first quarter. Jane Street Group LLC now owns 603,253 shares of the biotechnology company’s stock valued at $2,789,000 after acquiring an additional 376,862 shares during the last quarter. 683 Capital Management LLC grew its holdings in shares of Cellectis by 488.7% in the fourth quarter. 683 Capital Management LLC now owns 352,638 shares of the biotechnology company’s stock worth $2,863,000 after purchasing an additional 292,738 shares during the last quarter. Capital International Investors grew its holdings in shares of Cellectis by 18.9% in the fourth quarter. Capital International Investors now owns 1,592,054 shares of the biotechnology company’s stock worth $12,927,000 after purchasing an additional 252,718 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in Cellectis by 55.5% during the 4th quarter. Legal & General Group Plc now owns 337,201 shares of the biotechnology company’s stock worth $2,738,000 after acquiring an additional 120,369 shares in the last quarter. 40.55% of the stock is owned by institutional investors and hedge funds.
Shares of NASDAQ CLLS opened at $3.98 on Friday. Cellectis has a 52 week low of $2.85 and a 52 week high of $16.53. The company has a quick ratio of 3.73, a current ratio of 3.73 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average is $3.94 and its 200 day moving average is $5.86. The company has a market cap of $181.13 million, a price-to-earnings ratio of -1.35 and a beta of 2.24.
Cellectis Company Profile (Get Rating)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.
- Get a free copy of the StockNews.com research report on Cellectis (CLLS)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.